利伐沙班的作用与功效

The functions and efficacy of rivaroxaban:

Rivaroxaban tablets are a new type of anticoagulant drug whose main ingredient is rivaroxaban. The indications for Rivaroxaban tablets are:

1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Used to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. For use in adult patients with non-valvular atrial fibrillation who have one or more risk factors (such as congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets.

A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants. In patients undergoing major orthopedic surgery, 5/95th (percentile) PT was (NeopLastin) 13-25 seconds 2-4 hours after taking the tablet (when the effect is strongest) (baseline value before surgery was 12-15 seconds).

Usage and dosage of rivaroxaban: The recommended dose is 10 mg, once a day. If the wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.